Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Dyax Corp (NASDAQ:DYAX)

23.69
Delayed Data
As of Aug 28
 -0.20 / -0.84%
Today’s Change
9.19
Today|||52-Week Range
30.55
+68.49%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$3.5B

Company Description

Dyax Corp. is a biopharmaceutical company, which discovers, develops and commercializes treatments for hereditary angioedema (HAE) and other plasma-kallikrein-mediated (PKM) disorders. The company utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development. It offers KALBITOR for the treatment of acute attacks of HAE. The company also offers DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b clinical study to treat HAE prophylactically. Dyax was founded in 1995 and is headquartered in Burlington, MA.

Contact Information

Dyax Corp.
55 Network Drive
Burlington Massachusetts 01803
P:(617) 225-2500
Investor Relations:
(617) 250-5741

Employees

Shareholders

Mutual fund holders61.48%
Individual stakeholders6.88%
Other institutional38.34%

Top Executives

Gustav A. ChristensenPresident, Chief Executive Officer & Director
George V. MigauskyChief Financial Officer & Executive Vice President
Burt A. AdelmanChief Medical Officer, EVP-Research & Development
Andrew D. AsheSecretary, Executive VP & General Counsel
Todd BazemoreChief Commercial Officer & Executive VP